DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...
In back-to-back studies published in Nature, researchers from Purdue University and Columbia University report a naturally ...
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production ...
ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple. As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR) ...
Existing bacteria and archaea still our universal common ancestor’s ribosomal hibernation defense mechanism when nutrients ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
Eascra Biotech, a nanomedicine startup, has won first place at the TechConnect Bio in Space Innovation Challenge, held during the TechConnect World Innovation Conference and Expo on March 10-12, 2026, ...
GSK is sourcing early-stage science across a wide range of technologies and disease areas, while placing more selective bets ...
Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...
Ahead of the anticipated target engagement data for AX-0810 in the first half of 2026, the Company will showcase ProQR’s ...
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.
A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results